$46.82
0.01000.02%
Pre-Market: Jul 19, 6:04 PM EDT
15 minutes delayed
Comments
Loading...
Exact Sciences
EXASNASDAQ
Exact Sciences (NASDAQ:EXAS) Stock, Analyst Ratings, Price Targets, Forecasts
Exact Sciences Corp has a consensus price target of $86.77 based on the ratings of 25 analysts. The high is $155 issued by Oppenheimer on July 29, 2021. The low is $70 issued by BTIG on June 27, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Evercore ISI Group, and BTIG on July 17, 2024, July 2, 2024, and June 27, 2024, respectively. With an average price target of $72.33 between Goldman Sachs, Evercore ISI Group, and BTIG, there's an implied 54.49% upside for Exact Sciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Evercore ISI Group
BTIG
Scotiabank
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Exact Sciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/17/2024 | Buy Now | 60.19% | Goldman Sachs | Matthew Sykes | $88 → $75 | Maintains | Buy | Get Alert |
| 07/02/2024 | Buy Now | 53.78% | Evercore ISI Group | Vijay Kumar | $80 → $72 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 49.51% | BTIG | Mark Massaro | $80 → $70 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 49.51% | Scotiabank | Sung Ji Nam | → $70 | Initiates | → Sector Outperform | Get Alert |
| 06/26/2024 | Buy Now | 49.51% | BTIG | Mark Massaro | $80 → $70 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 70.87% | BTIG | Mark Massaro | $85 → $80 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 81.55% | Canaccord Genuity | Kyle Mikson | $90 → $85 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 70.87% | Citigroup | Patrick Donnelly | $100 → $80 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 113.58% | Citigroup | Patrick Donnelly | → $100 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 92.23% | Canaccord Genuity | Kyle Mikson | $100 → $90 | Maintains | Buy | Get Alert |
| 01/02/2024 | Buy Now | 94.36% | Benchmark | Bruce Jackson | → $91 | Upgrade | Hold → Buy | Get Alert |
| 12/14/2023 | Buy Now | 92.23% | Guggenheim | Subbu Nambi | → $90 | Initiates | → Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
| 11/03/2023 | Buy Now | 92.23% | Goldman Sachs | Matthew Sykes | $100 → $90 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | 70.87% | Piper Sandler | David Westenberg | $90 → $80 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | 92.23% | Piper Sandler | David Westenberg | → $90 | Upgrade | Neutral → Overweight | Get Alert |
| 09/28/2023 | Buy Now | 77.27% | Bernstein | Eve Burstein | → $83 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 92.23% | Piper Sandler | David Westenberg | $80 → $90 | Maintains | Neutral | Get Alert |
| 08/03/2023 | Buy Now | 134.94% | Jefferies | Brandon Couillard | $100 → $110 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 92.23% | Credit Suisse | Dan Leonard | $75 → $90 | Maintains | Neutral | Get Alert |
| 08/02/2023 | Buy Now | 158.44% | Baird | Catherine Schulte | $99 → $121 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | — | Benchmark | Bruce Jackson | — | Downgrade | Buy → Hold | Get Alert |
| 07/24/2023 | Buy Now | 134.94% | Goldman Sachs | Matthew Sykes | $85 → $110 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 134.94% | Goldman Sachs | Matthew Sykes | $85 → $110 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | 145.62% | Canaccord Genuity | Kyle Mikson | $92 → $115 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | 177.66% | Citigroup | Patrick Donnelly | $100 → $130 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | 105.04% | Benchmark | Bruce Jackson | → $96 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2023 | Buy Now | 81.55% | Stifel | Daniel Arias | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2023 | Buy Now | 96.5% | Canaccord Genuity | Kyle Mikson | → $92 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 113.58% | Jefferies | Brandon Couillard | $82 → $100 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 113.58% | Citigroup | Patrick Donnelly | $90 → $100 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 75.14% | Jefferies | Brandon Couillard | $72 → $82 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 87.95% | B of A Securities | Derik De Bruin | $80 → $88 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 60.19% | Credit Suisse | Dan Leonard | $70 → $75 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 111.45% | Baird | Catherine Schulte | $92 → $99 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 81.55% | Craig-Hallum | Alex Nowark | $55 → $85 | Upgrade | Hold → Buy | Get Alert |
| 05/05/2023 | Buy Now | 55.92% | UBS | Elizabeth Garcia | → $73 | Initiates | → Neutral | Get Alert |
| 03/15/2023 | Buy Now | 66.6% | Benchmark | Bruce Jackson | $54 → $78 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | 92.23% | Citigroup | Patrick Donnelly | $70 → $90 | Upgrade | Neutral → Buy | Get Alert |
| 03/03/2023 | Buy Now | 49.51% | Piper Sandler | David Westenberg | $50 → $70 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 62.32% | Cowen & Co. | Dan Brennan | $56 → $76 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | 96.5% | Baird | Catherine Schulte | $89 → $92 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | 70.87% | BTIG | Mark Massaro | $85 → $80 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 60.19% | Canaccord Genuity | Kyle Mikson | $70 → $75 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 49.51% | Citigroup | Patrick Donnelly | $35 → $70 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 49.51% | Credit Suisse | Dan Leonard | → $70 | Reiterates | → Neutral | Get Alert |
| 02/10/2023 | Buy Now | 49.51% | Credit Suisse | Dan Leonard | $50 → $70 | Downgrade | Outperform → Neutral | Get Alert |
| 01/18/2023 | Buy Now | — | Raymond James | Andrew Cooper | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/12/2023 | Buy Now | 60.19% | SVB Leerink | Puneet Souda | $70 → $75 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | 49.51% | SVB Leerink | Puneet Souda | $60 → $70 | Maintains | Outperform | Get Alert |
| 12/16/2022 | Buy Now | 49.51% | Jefferies | Brandon Couillard | → $70 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 6.79% | Piper Sandler | David Westenberg | $40 → $50 | Maintains | Neutral | Get Alert |
| 11/08/2022 | Buy Now | 28.15% | Raymond James | Andrew Cooper | $70 → $60 | Maintains | Outperform | Get Alert |
| 11/07/2022 | Buy Now | 38.83% | BTIG | Mark Massaro | $70 → $65 | Maintains | Buy | Get Alert |
| 10/19/2022 | Buy Now | — | Craig-Hallum | Alexander Nowak | — | Downgrade | Buy → Hold | Get Alert |
| 08/25/2022 | Buy Now | 17.47% | Credit Suisse | Dan Leonard | → $55 | Initiates | → Outperform | Get Alert |
| 08/17/2022 | Buy Now | -14.57% | Piper Sandler | David Westenberg | $50 → $40 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 28.15% | Craig-Hallum | Alex Nowark | $81 → $60 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 43.1% | Cowen & Co. | Dan Brennan | $83 → $67 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 49.51% | BTIG | Mark Massaro | $100 → $70 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 60.19% | Baird | Catherine Ramsey | $90 → $75 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 6.79% | Citigroup | Patrick Donnelly | $65 → $50 | Maintains | Neutral | Get Alert |
| 08/03/2022 | Buy Now | 49.51% | Raymond James | Andrew Cooper | $80 → $70 | Maintains | Outperform | Get Alert |
| 06/03/2022 | Buy Now | 6.79% | Piper Sandler | David Westenberg | → $50 | Initiates | → Neutral | Get Alert |
| 04/27/2022 | Buy Now | 102.9% | B of A Securities | Derik De Bruin | $105 → $95 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | 70.87% | Raymond James | Andrew Cooper | $90 → $80 | Maintains | Outperform | Get Alert |
| 04/27/2022 | Buy Now | 102.9% | SVB Leerink | Puneet Souda | $130 → $95 | Maintains | Outperform | Get Alert |
| 04/19/2022 | Buy Now | 81.55% | Goldman Sachs | Matthew Sykes | $100 → $85 | Maintains | Buy | Get Alert |
| 02/23/2022 | Buy Now | 70.87% | Wells Fargo | Dan Leonard | $95 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/23/2022 | Buy Now | 70.87% | Citigroup | Patrick Donnelly | $100 → $80 | Maintains | Neutral | Get Alert |
| 02/23/2022 | Buy Now | 92.23% | Raymond James | Andrew Cooper | $130 → $90 | Maintains | Outperform | Get Alert |
| 02/23/2022 | Buy Now | 177.66% | SVB Leerink | Puneet Souda | $140 → $130 | Maintains | Outperform | Get Alert |
| 11/03/2021 | Buy Now | 102.9% | Wells Fargo | Dan Leonard | — | Maintains | Equal-Weight | Get Alert |
| 11/03/2021 | Buy Now | 199.02% | SVB Leerink | Puneet Souda | — | Maintains | Outperform | Get Alert |
| 11/03/2021 | Buy Now | 177.66% | Raymond James | Andrew Cooper | — | Downgrade | Strong Buy → Outperform | Get Alert |
| 07/29/2021 | Buy Now | 241.73% | Canaccord Genuity | Kyle Mikson | — | Maintains | Buy | Get Alert |
| 07/29/2021 | Buy Now | 231.06% | Oppenheimer | Kevin DeGeeter | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Exact Sciences (EXAS) stock?
The latest price target for Exact Sciences (NASDAQ:EXAS) was reported by Goldman Sachs on July 17, 2024. The analyst firm set a price target for $75.00 expecting EXAS to rise to within 12 months (a possible 60.19% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exact Sciences (EXAS)?
The latest analyst rating for Exact Sciences (NASDAQ:EXAS) was provided by Goldman Sachs, and Exact Sciences maintained their buy rating.
When was the last upgrade for Exact Sciences (EXAS)?
The last upgrade for Exact Sciences Corp happened on January 2, 2024 when Benchmark raised their price target to $91. Benchmark previously had a hold for Exact Sciences Corp.
When was the last downgrade for Exact Sciences (EXAS)?
The last downgrade for Exact Sciences Corp happened on August 2, 2023 when Benchmark changed their price target from N/A to N/A for Exact Sciences Corp.
When is the next analyst rating going to be posted or updated for Exact Sciences (EXAS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exact Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exact Sciences was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.
Is the Analyst Rating Exact Sciences (EXAS) correct?
While ratings are subjective and will change, the latest Exact Sciences (EXAS) rating was a maintained with a price target of $88.00 to $75.00. The current price Exact Sciences (EXAS) is trading at is $46.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.